Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
QUILT-3.055
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
- NCT03228667 ↗
- Active, not recruiting
- ImmunityBio, Inc.
- Focused
We haven't built an HCP commentary report on QUILT-3.055 (N-803 + pembrolizumab, N-803 + nivolumab and 10 more in Non-Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on QUILT-3.055 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Renal Cell Carcinoma; Gastric Cancer; Cervical Cancer; Hepatocellular Carcinoma; Microsatellite Instability; Mismatch Repair Deficiency; Colorectal Cancer
- Interventions
- N-803 + Pembrolizumab; N-803 + Nivolumab; N-803 + Atezolizumab; N-803 + Avelumab; N-803 + Durvalumab; N-803 + Pembrolizumab + PD-L1 t-haNK; N-803 + Nivolumab + PD-L1 t-haNK; N-803 + Atezolizumab + PD-L1 t-haNK; N-803 + Avelumab + PD-L1 t-haNK; N-803 + Durvalumab + PD-L1 t-haNK; N-803 + Docetaxel + Pembrolizumab; N-803 + Docetaxel + Nivolumab
- Arms
- Cohort 1 · Other
- Cohort 2 · Other
- Cohort 3 · Other
- Cohort 4 · Experimental
- Cohort 5 · Experimental
- Cohort 6 · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.
- Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μ
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 11, 2018
- Primary completion
- Aug 31, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT03228667 · updated Jan 14, 2026